Result: Risk Minimisation Materials for medicines starting with the letter B
Bavencio
Merck - Pfizer

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Alert Card
Patient Alert Card - myasthenia gravis update

Bavencio 20 mg/ml concentrate for solution for infusion (avelumab) – Patient Information Brochure
Patient Information Brochure - Important safety information to minimise the risk of immune-related side effects - myasthenia gravis update
Benepali
Biogen Biosimilars

Benepali Healthcare Professional Training Guide
Brief Training on additional risk minimization measures for HCPs
For Healthcare Professionals

Benepali Patient Alert Card
PAC contains important information that patients need to be aware of.

Benepali Quick Reference Guide for pre-filled pen
This guide is designed to offer quick reference on how to inject safely and effectively.

Benepali Quick Reference Guide for pre-filled syringe
This guide offers quick reference on how to inject safely and effectively.
Beovu
Novartis Pharmaceuticals UK Ltd

Beovu (Brolucizumab) - Patient Guide to Therapy - for patients
This guide contains important information about Beovu (Brolucizumab) why its been prescribed, side effects and their potential risks.
Bimizza
Morningside Healthcare Ltd

Checklist for Prescribers - Bimizza 150 microgram/20 microgram Tablets
Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. •Thromboembolism (e.g. deep vein thrombosis, pulmonary embolism, heart attack and stroke) is a rare but important risk with use of a CHC.
For Healthcare Professionals

Important Information for Women Leaflet - Bimizza 150 microgram/20 microgram Tablets
All women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

Patient Alert Card - Bimizza 150 microgram/20 microgram Tablets
IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES
Bivalirudin
Accord Healthcare Limited

Bivaluridin Accord dosing and administration instruction for medically managed ACS patients with urgent or early intervention
This document will serve as a guide to HCP on dosing and administration of Bivaluridin Accord for medically managed ACS patients with urgent or early intervention.
For Healthcare Professionals

Bivaluridin Accord dosing and administration instruction for PCI and Primary PCI
This document will provide instruction for dosing and administration of Bivaluridin Accord following PCI and primary PCI
For Healthcare Professionals

Direct Healthcare Professional Communication on approved dosing regimens for Accord Bivalirudin for Percutaneous Coronary Intervention (PCI), following reports of inappropriate use
This letter will provide guidance on the dosing regimen, administration instructions, safety concerns and suspected adverse reactions to HCPs for patients undergoing Percutaneous Coronary Intervention (PCI).
For Healthcare Professionals
Cipla EU Ltd

Bivaluridin Education Material for medically managed ACS patients
Bivaluridin Education Material for medically managed ACS patients: Treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Bivalirudin should be administered with acetylsalicylic acid and clopidogrel.
For Healthcare Professionals

Bivaluridin Education Material for PCI and Primary PCI
After reconstitution 1ml contains 50mg bivalirudin. After dilution 1ml contains 5mg bivalirudin. Indications: Bivalirudin is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Bivalirudin is also indicated for the treatment of adult patients with unstable angina/ non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Bivalirudin should be administered with acetylsalicylic acid and clopidogrel.
For Healthcare Professionals
Blincyto
Amgen Ltd

BLINCYTO Guide for Nurses
This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441
For Healthcare Professionals

BLINCYTO Guide for Patients and Caregivers
This educational brochure contains important information you should know before receiving BLINCYTO. This educational material is essential to ensure the safe and effective use of the drug and appropriate management of the important selected risks. Please read it carefully before taking the medicinal product. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441

BLINCYTO Guide for Pharmacists
This educational brochure contains important information regarding the reconstitution and preparation procedures for blinatumomab. To ensure the safe and effective use of the medicinal product and appropriate management of the important selected risks, please carefully read this material before reconstituting and preparing of the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441
For Healthcare Professionals

BLINCYTO Guide for Physicians
This educational brochure contains important information regarding the administration of BLINCYTO and the risks of medication errors and neurologic events. This educational material is essential to ensure the safe and effective use of the product and appropriate management of the important selected risks and therefore it is advised to be read carefully before prescribing and administering the medicinal product.To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441
For Healthcare Professionals

BLINCYTO Patient Alert Card
This BLINCYTO patient alert card contains a warning message for HCPs that the patient is using BLINCYTO, includes contact details of the BLINCYTO prescriber and treatment start date, and information on the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441
Bosentan
Cipla EU Ltd

Bosentan 62.5 mg and 125 mg film-coated tablets Prescribers guide
This Prescriber’s Guide provides a summary of the most important safety information you should know about bosentan and the following important risks associated with bosentan treatment and how to minimise them
For Healthcare Professionals

Patient card - Bosentan 62.5mg and 125mg film‐coated Tablets
Important Safety Alerts for Patients taking Bosentan Tablets (bosentan)
For Healthcare Professionals
Aurobindo Pharma - Milpharm Ltd.

Bosentan Milpharm - Patient Alert Card
Important Safety Alerts for Patients taking Bosentan Milpharm
Mylan

Bosentan Mylan - Important Safety Information for Prescribers
This guide includes important safety information which must be considered before a patient is prescribed Bosentan Mylan.
For Healthcare Professionals

Bosentan Patient Alert Card
Important Safety Alerts for Patients taking Bosentan Mylan (bosentan)
Accord Healthcare Limited

Bosentan Patient Alert Card
Important Safety Alerts for Patients taking Bosentan Accord (bosentan)
Zentiva

Bosentan- Patient Alert Guide
This card contains important information about bosentan. Please read this card carefully before starting your treatment with bosentan. For hard copies please contact our medical information department on 0800 090 2408 or email [email protected]
Dr. Reddy's Laboratories (UK) Ltd

Braltus
Teva UK Limited

Risk Minimisation Information on Potential Risk of Medication Errors - Guide for HCPs
This educational guide is provided to highlight and minimise the potential risk of prescribing and administration errors (medication errors) due to the differences between Braltus (tiotropium bromide) and the originator product Spiriva® HandiHaler® (tiotropium bromide) with respect to the pre-metered dose.
For Healthcare Professionals
Brancico
Zentiva

Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets Educational material for health care professionals
Educational material for health care professionals Brancico XL 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets For hard copies please contact our medical information department at 0800 090 2408 or email [email protected]
For Healthcare Professionals
Brinavess
Correvio UK Ltd

Appropriate use of Brinavess - Healthcare Professional Card
Appropriate use of Brinavess - Healthcare Professional Card Brinavess 20 mg/ml concentrate for solution for infusion (vernakalant hydrochloride)
For Healthcare Professionals
Bronchitol
Pharmaxis Europe Limited

Bronchitol Healthcare Professional Leaflet
Bronchitol Healthcare Professional Leaflet
For Healthcare Professionals